Septerna, Inc. (SEPN)
Develops oral drugs targeting cell receptors to treat hormonal, immune, and metabolic diseases.
$33.97+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+178.2%
The outlook
Septerna trades near the upper end of its 52-week range, with the price comfortably above both its 50- and 200-day moving averages. Analyst consensus is strongly bullish, with an average price target implying roughly 32% upside from current levels. The stock's technical positioning and analyst sentiment both lean decidedly positive.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range85% of the way from its 52-week low to high
Price targetAvg target +32% vs current price
Analyst price target
~12-month · 9 analysts$45.00average target+32.5% vs now
Now $33.97
Low $38.00High $60.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.53B
52-wk high
$38.04
52-wk low
$10.62
50-day avg
$32.72
200-day avg
$27.03
Trailing P/E
—